iSpecimen Inc. (NASDAQ:ISPC) Short Interest Update

iSpecimen Inc. (NASDAQ:ISPC) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totaling 5,529,018 shares, an increase of 852.0% from the March 31st total of 580,752 shares. Approximately 21.2% of the shares of the company are sold short. Based on an average trading volume of 52,965,631 shares, the short-interest ratio is presently 0.1 days.

Hedge Funds Weigh In On iSpecimen

An institutional investor recently bought a new position in iSpecimen stock. Scientech Research LLC bought a new position in shares of iSpecimen Inc. (NASDAQ:ISPC) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned approximately 0.30% of iSpecimen at the end of the most recent quarter. 13.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of iSpecimen in a research note on Tuesday. One research analyst has rated the stock with a Sell rating, According to MarketBeat, iSpecimen has an average rating of “Sell”.

iSpecimen Price Performance

Shares of ISPC stock traded down $0.03 during trading hours on Friday, reaching $0.13. 27,448,865 shares of the company’s stock were exchanged, compared to its average volume of 22,726,467. The company has a market cap of $3.87 million, a P/E ratio of -0.06 and a beta of 1.98. The company’s 50 day moving average is $0.20 and its two-hundred day moving average is $0.40. iSpecimen has a 1 year low of $0.10 and a 1 year high of $3.18.

iSpecimen (NASDAQ:ISPC) last issued its earnings results on Wednesday, April 1st. The company reported ($0.74) earnings per share (EPS) for the quarter. The business had revenue of $0.05 million for the quarter. iSpecimen had a negative return on equity of 496.31% and a negative net margin of 543.37%.

iSpecimen Company Profile

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.